Howard S Hochster, MD

André T et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27(19):3109-16. Abstract

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years. Proc ASCO 2007b. No abstract available.

Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007;25(16):2198-204. Abstract

O’Connell JB et al. Colon cancer survival rates with the new American Joint Committee on Cancer Sixth Edition Staging. JNCI 2004;96(19):1420-5. Abstract

O’Connell M et al. Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox). Proc ASCO 2012;Abstract 3512.

Tournigand C et al. Adjuvant therapy with fluorouracil and oxaliplatin in Stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer. J Clin Oncol 2012;30(27):3353-60. Abstract

John L Marshall, MD

Arnold D et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). Proc ASCO 2012;Abstract CRA3503.

Bennouna J et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37. Abstract

Cohn AL et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). Proc ASCO 2010;Abstract 3596.

De Roock W et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304(16):1812-20. Abstract

Grothey A et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26(33):5326-34. Abstract

Eric Van Cutsem, MD, PhD

Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626-34. Abstract

Arnold D et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). Proc ASCO 2012;Abstract CRA3503.

Douillard J et al. Final results from PRIME — A Phase III study of panitumumab with FOLFOX4 for first-line mCRC. Proc ASCO 2011;Abstract 3510.

Ellis LM et al. VEGF-targeted therapy: Mechanisms of anti-tumor activity. Nat Rev Cancer 2008;8:579-91. Abstract

Giantonio BJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007;25(12):1539-44. Abstract

Goldberg RM et al. The continuum of care: A paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12(1):38-50. Abstract

Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23(36):9441-2. Abstract

Holash J et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. PNAS 2002;99:11393-8. Abstract

Karapetis CS et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65. Abstract

Khayat D et al. Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumors: Results from the expansion cohort of a phase I study. Eur J Cancer 2013;49(4):790-7. Abstract

Pericay C et al. Phase 2 randomized, noncomparative, open-label, study of aflibercept and modified FOLFOX6 in the first-line treatment of metastatic colorectal cancer (AFFIRM). ESMO 14th World Congress on Gastrointestinal Cancer 2012;Abstract O-0024.

Tew WP et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010;16(1):358-66. Abstract

Van Cutsem E et al. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumors. Eur J Cancer 2013;49:17-24. Abstract

Van Cutsem E et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506. Abstract

Van Cutsem E et al. Lessons from the adjuvant bevacizumab trial on colon cancer: What next? J Clin Oncol 2011;29(1):1-4. Abstract

Van Cutsem E et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010;21(Suppl 5):v93-7. Abstract

Richard M Goldberg, MD

Grothey A. S-1 in colorectal cancer: A new standard of care? Lancet Oncol 2012;13(11):1068-70. Abstract

Siena S et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. JNCI 2009;101(19):1308-24. Abstract

Josep Tabernero, MD

Abad A et al. Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncol 2008;47(2):286-92. Abstract

Alberts SR et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study. J Clin Oncol 2005;23(36):9243-9. Abstract

Barone C et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 2007;97(8):1035-9. Abstract

Bokemeyer C et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27(5):663-71. Abstract

Falcone A et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25(13):1670-6. Abstract

Folprecht G et al. Randomized multicenter study of cetuximab plus FOLFOX or cetuximab plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal cancer liver metastases (CELIM-study). Proc ESMO 2011. No abstract available

Folprecht G et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 2010;11(1):38-47. Abstract

Masi G et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006;13(1):58-65. Abstract

Okines A et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer — First BEAT and the randomized phase-III NO16966 trial. Br J Cancer 2009;101(7):1033-8. Abstract

Saltz LB et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26(12):2013-9. Abstract

Seium Y et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: A Phase I-II study. Ann Oncol 2005;16(5):762-6. Abstract

Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22(2):229-37. Abstract

Van Cutsem E et al. Outcome according to metastatic site in patients with KRAS wild-type tumors: Analysis from the CRYSTAL and OPUS studies. Gastrointestinal Cancers Symposium 2011;Abstract 472.

Van Cutsem E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17. Abstract

Ychou M et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): A phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008;62(2):195-201. Abstract